Home > Healthcare > Medical Devices > Therapeutic Devices > Artificial Pancreas Device Systems (APDS) Market

Artificial Pancreas Device Systems (APDS) Market Analysis

  • Report ID: GMI6912
  • Published Date: Oct 2023
  • Report Format: PDF

Artificial Pancreas Device Systems Market Analysis:

Artificial Pancreas Device Systems Market, By Device Type, (USD Million)

To understand key trends  
Download Free Sample
 

The market by device type is categorized into threshold suspend device systems, control-to-range (CTR) systems, control-to-target (CTT) systems. The threshold suspends device systems segment garnered USD 175 million revenue size in the year 2022. The dominance of the segment can be attributed to their advanced safety features.
 

  • These systems automatically suspend insulin delivery while blood glucose levels reach a predetermined threshold, effectively preventing a life-threatening condition.
     
  • The safety aspect strongly resonates with both healthcare providers and patients, thereby increasing the adoption of APDS.
     

Thus, the reduced hypoglycemic events and enhanced patient safety has been a key driver for market development.
 

Artificial Pancreas Device Systems Market Share, By End-use, 2022

To understand key market trends  
Download Free Sample
 

Based on end-use, the artificial pancreas device systems market is segmented into hospitals and clinics, homecare, and others. The hospitals and clinics segment garnered USD 102 million revenue size in the year 2022.
 

  • Growth of hospital and clinics segment can be attributed to their clinical expertise, ability to provide continuous patient monitoring, access to advanced medical technology, active involvement in research and clinical trials, facilitation of insurance coverage, and their crucial role in patient education and awareness.
     
  • The presence of skilled healthcare professionals in these settings ensures proper training and support for APDS users, enhancing patient safety and comfort.
     
  • Additionally, hospitals and clinics serve as hubs for critical research that validate the effectiveness of APDS, thereby promoting greater clinical endorsement and market demand.
     
  • Their established relationships with insurance providers further encourage patients to adopt APDS, making it a preferred choice for diabetes management.
     

Therefore, segments contributions create a conducive environment for APDS adoption and contribute significantly to the market size.
 

U.S. Artificial Pancreas Device Systems Market Size, 2020 -2032 (USD Million)

To understand regional trends  Download Free Sample
 

U.S. artificial pancreas device systems market accounted for USD 122 million revenue size in 2022 and is predicted to witness substantial market growth.
 

  • Surge in the diabetes population base in the U.S. is one of the primary factors driving the market expansion in the country.
     
  • The presence of a stringent but well-defined regulatory framework by the U.S. FDA ensures safety and efficacy of artificial pancreas device systems, instilling confidence in healthcare providers and patients alike
     
  • Additionally, greater patient awareness, access to healthcare, health insurance coverage, and a growing demand for advanced diabetes management solutions have all played a pivotal role in propelling the market's trends and establishing the U.S. as a dominant force in this vital healthcare sector.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global artificial pancreas device systems industry was valued at USD 331 million in 2022 and is estimated to account for USD 757.5 million by 2032.

The threshold suspends device systems segment garnered USD 175 million in 2022 and will grow through 2032 attributed to the advanced safety features of these devices.

U.S. artificial pancreas device systems industry accounted for USD 122 million in 2022 and is predicted to witness substantial growth through 2032 due to the surge in the diabetes population base in the country.

Medtronic Plc, Johnson & Johnson Services Inc., Bigfoot Biomedical, Tandem Diabetes Care, Inc., Pancreum, Inc., TypeZero Technologies, LLC, Beta Bionics, Insulet Corporation, Defymed, Inreda Diabetic, and Diabeloop.

Artificial Pancreas Device Systems Market Scope

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 11
  • Tables & Figures: 218
  • Countries covered: 22
  • Pages: 175
 Download Free Sample